磷酰二胺吗啉代寡核苷酸固相合成工艺优化OACSTPCD
Optimization of solid-phase synthesis process of phosphorodiamidate morpholino oligonucleotides
目的 对磷酰二胺吗啉代寡核苷酸(PMO)固相合成工艺进行优化,确定最佳固相合成反应条件.方法 采用现有方法合成PMO四聚体PMO-TTTT,经过半制备高效液相色谱法纯化,并经核磁共振氢谱和高分辨质谱确证结构.利用纯化的PMO-TTTT作为标准品建立标准曲线,以此为基础对固相合成偶联反应过程中有机碱、添加剂、反应时间、反应温度等反应条件进行优化.使用优化后的条件合成抗甲型流感病毒PMO序列PMO-flu,并使用核酸纯化仪对样品进行纯化.结果 确立了有机碱N-乙基吗啉、添加剂LiI、反应温度30 ℃、反应时间90 min作为PMO固相合成的最佳反应条件,并以该反应条件合成了抗流感病毒PMO序列PMO-flu.结论 发现了一种能够有效提高PMO固相合成效率的偶联反应添加剂LiI,确立了 PMO固相合成工艺方法,为后续PMO的高效制备奠定了基础.
Objective To optimize the solid-phase synthesis process of phosphorodiamidate morpholino oligonucleotide(PMO)and determine the optimal reaction conditions.Methods The PMO tetramer PMO-TTTT was synthesized according to the reported reaction conditions,followed by purification through a semi-preparative high-performance liquid chromatography(HPLC)process.PMO-TTTT was structurally verified using nuclear magnetic resonance(NMR)and high-resolution mass spectrometry.With purified PMO-TTTT as a reference,a calibration curve was established,which subsequently guided the optimization of the reaction conditions for the solid-phase coupling reaction process,including the organic base,additives,duration of reaction and temperature.Under the optimized reaction condition,the anti-influenza A virus PMO sequence,PMO-flu,was synthesized and purified using a nucleic acid purification device.Results The optimal parameters for PMO solid-phase synthesis were determined.The organic base was N-ethylmorpholine,the additive was lithium iodide,the best temperature was 30 ℃,and the duration was 90 minutes.Conclusion The PMO solid-phase synthesis process has been established.LiI has been screened as a potent coupling reaction additive which could significantly boosts the efficiency of PMO solid-phase synthesis.
龙仁杰;王保刚;宋亚彬
安徽医科大学,合肥 230032军事科学院军事医学研究院,病原微生物生物安全全国重点实验室,北京 100071安徽医科大学,合肥 230032||军事科学院军事医学研究院,病原微生物生物安全全国重点实验室,北京 100071
药学
固相合成磷酰二胺吗啉代寡核苷酸工艺优化
solid-phase synthesisphosphorodiamidate morpholino oligonucleotidesprocess optimization
《军事医学》 2024 (009)
664-670 / 7
国家科技重点专项重大新药创制项目(2015ZX09102022)
评论